National Bank of Canada’s Design Therapeutics DSGN Stock Holding History

National Bank of Canada’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$96	Buy	+9	New	+$91	﹤0.01%	2837

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

National Bank of Canada's DSGN Position: Q1 2026 in Review

National Bank of Canada opened a new position in Design Therapeutics (DSGN) in Q1 2026: 9 shares worth $96. The stake represents ﹤0.01% of the portfolio and ranks #2837 among its holdings.

125 funds tracked by Wall St. Rank hold DSGN as of Q1 2026.

National Bank of Canada held 9 shares of Design Therapeutics worth $96 as of Q1 2026.
Design Therapeutics was a new National Bank of Canada position in Q1 2026.
Design Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2837 holding.
125 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.